Quintrio
Home

WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES

Henry Schein Inc

HSIC

Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.

Last trade $83.90
Day change -$1.065 (-1.25%)
Day range $81.58 – $86.66
Volume 670,498
Market cap $9.39B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$9.39B
Price / earnings
22.31×
Price / book
2.97×
Price / sales
0.68×
EV / sales
0.93×
EV / EBITDA
11.29×

Profitability

Earnings per share
$3.81
Return on assets
3.66%
Return on equity
13.33%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.12×
Current ratio
1.33×
Quick ratio
0.76×
Cash ratio
0.05×

Cash flow

Price / cash flow
13.67×
Price / free cash flow
16.8×
Free cash flow
$559M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HSIC, quarterly periods
Line itemQ3 FY2026 Sep 26, 2026Q2 FY2026 Jun 27, 2026Q1 FY2026 Mar 28, 2026Q4 FY2025 Dec 27, 2025Q3 FY2025 Sep 27, 2025Q2 FY2025 Jun 28, 2025Q1 FY2025 Mar 29, 2025Q4 FY2024 Dec 28, 2024
Revenue$3.47B$3.46B$3.37B$3.44B$3.34B$3.24B$3.17B$3.19B
Cost of revenue$2.37B$2.36B$2.3B$2.37B$2.31B$2.22B$2.17B$2.2B
Gross profit$1.11B$1.1B$1.07B$1.06B$1.03B$1.02B$1B$993M
Selling, general and administrative$819M$831M$809M$808M$760M$778M$738M$738M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$912M$930M$888M$900M$862M$865M$825M$838M
Operating income$193M$171M$182M$163M$164M$151M$175M$155M
Interest expense-$42M-$43M-$39M-$39M-$38M-$38M-$35M-$35M
Income before taxes$163M$136M$150M$133M$137M$125M$148M$126M
Income taxes$37M$34M$38M$32M$28M$31M$35M$31M
Net income$126M$102M$112M$103M$109M$94M$113M$96M
Net income attributable to common shareholders$119M$94M$107M$101M$101M$86M$110M$94M
EBITDA$301M$284M$275M$268M$278M$250M$273M$268M
Basic earnings per share$1.07$0.83$0.93$0.86$0.84$0.71$0.89$0.75
Diluted earnings per share$1.06$0.82$0.92$0.85$0.84$0.70$0.88$0.75

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Is Henry Schein (HSIC) a Solid Growth Stock? 3 Reasons to Think "Yes"

Henry Schein (HSIC) has been identified as an attractive growth stock by Zacks' proprietary system, earning a Zacks Rank #2 (Buy) and Growth Score of B. The company demonstrates strong fundamentals including projected EPS growth of 10.6% (vs. industry average of 5.3%), efficient asset utilization with an S/TA ratio of 1.21 (vs. industry average of 0.77), and positive earnings estimate revisions with current-year estimates up 3.5% over the past month. Sales are expected to grow 5% this year compared to the industry average of 2.6%.

Zacks Investment Research

Henry Schein (HSIC) Upgraded to Buy: What Does It Mean for the Stock?

Henry Schein (HSIC) has been upgraded to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate for fiscal year 2026 remains at $5.50 per share, with analysts raising estimates by 3.6% over the past three months. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation driven by improving business fundamentals.

Zacks Investment Research

HSIC vs. MMSI: Which Stock Should Value Investors Buy Now?

In a comparison of two medical-dental supplies stocks, Henry Schein (HSIC) emerges as the better value opportunity compared to Merit Medical (MMSI). HSIC holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a lower forward P/E ratio of 16.05 and a PEG ratio of 1.56. MMSI, ranked #3 (Hold) with a Value grade of C, has a higher forward P/E of 21.06 and PEG ratio of 1.98, making HSIC more attractive to value investors.

Zacks Investment Research

Henry Schein (HSIC) Tops Q3 Earnings Estimates

Henry Schein reported Q3 2026 earnings of $1.56 per share, beating consensus estimates of $1.34 by 16.42%, with revenues of $3.47 billion meeting expectations. The stock has outperformed the S&P 500 by 4.4% year-to-date. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions. Becton Dickinson is expected to report results on November 5 with projected earnings of $4.06 per share, though revenues are expected to decline 13% year-over-year.

Zacks Investment Research

Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term

Henry Schein (HSIC), a healthcare solutions company, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and an A VGM Score. The stock has shown positive momentum with a 1.8% gain over the past four weeks and an average earnings surprise of +6.5%, making it noteworthy for momentum investors despite its Hold rating.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 8, 20191,275-for-1,000forward split
Sep 15, 20172-for-1stock dividend
Mar 1, 20052-for-1forward split